Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setmelanotide in POMC or PCSK1 Deficiency Obesity
NCT02896192Phase 3Completed
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Feb 2017
- Primary completion
- May 2020
- Countries
- 7
01
Overview
Phase 3, double-blind trial of setmelanotide in pro-opiomelanocortin deficiency and proprotein convertase subtilisin/kexin type 1 deficiency, sponsored by Rhythm Pharmaceuticals. Primary endpoint: Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year. Started Feb 2017; status: completed.
02
Drugs
setmelanotide
03
Conditions
pro-opiomelanocortin deficiencyproprotein convertase subtilisin/kexin type 1 deficiency
Beyond the preview
Go deeper on NCT02896192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02896192.